India Made AstraZeneca’s COVID-19 Vaccine Not Eligible For EU Travel, Seeks Resolution: Reuters
Serum Institute of India’s (SII) CEO Adar Poonawalla said he was trying to resolve EU travel problems facing Indians inoculated…
UK Study Of COVID-19 Shots Mix-Match Shows Immune Response, Can Add Flexibility To Vaccination Programs: CNBC
Mixing and matching the coronavirus vaccines made by Pfizer Inc (NYSE:PFE) – BioNTech SE (NASDAQ:BNTX) and AstraZeneca Plc (NASDAQ:AZN) – Oxford showed a “robust”…
AstraZeneca COVID-19 Vaccine Shows Higher Immune Response With Longer Gap, Third Booster Dose
A sub-analysis from the Oxford-led COV001 and COV002 trials with AstraZeneca Plc (NASDAQ:AZN) COVID-19 vaccine induced strong immune responses following a prolonged second…
Nanomedicine Company Makes “Nanomachines” that Attack Viruses
Photo by Fusion Medical Animation on Unsplash
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.
Moderna Files For U.S. Patent Titled ‘BROAD SPECTRUM INFLUENZA VIRUS VACCINE’
https://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&u=%2Fnetahtml%2FPTO%2Fsearch-adv.html&r=8724&p=175&f=G&l=50&d=PG01&S1=20210624.PD.&OS=PD/20210624&RS=PD/20210624
Argus Research Maintains Buy on Moderna, Raises Price Target to $230
Argus Research analyst Jasper Hellweg maintains Moderna (NASDAQ:MRNA) with a Buy and raises the price target from $200 to $230.
‘Fast Money Halftime Report’ Picks For June 23
On CNBC's "Fast Money Halftime Report," Stephen Weiss said the news from the CDC on Moderna Inc (NASDAQ: MRNA) is insignificant. He sees a buying opportunity.